Further research on these inhibitors in vitro and in vivo would thus certainly be of interest, especially in the field of CML, and could potentially ameliorate sensitivity towards TKI treatment or successful TFR through upregulation of NK cell activity. Here, TFRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.